Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SOLESENCE, INC.NANX · Entity 7041 | Chief Operating Officer | June 05, 2025 | June 06, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SOLESENCE, INC.
Report date June 05, 2025 · Filed June 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 196,905 |
Reported balance
After 2025-06-05 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2025-06-05 · Exercise / conversion · Acquired 4,693 · Balance 196,905 |
| Common StockSEC Table I · non-derivative | Direct | 192,212 |
Reported balance
After 2025-06-05 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2025-06-05 · Sale · Disposed 4,693 · Balance 192,212 F1: These 4,693 shares were sold through fifty trades at prices ranging from $3.95 to $3.99 per share. The average of all trades was $3.96 per share as shown. |
| Common StockSEC Table I · non-derivative | Direct | 231,019 |
Reported balance
After 2025-06-06 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2025-06-06 · Exercise / conversion · Acquired 38,807 · Balance 231,019 |
| Common StockSEC Table I · non-derivative | Direct | 192,212 |
Reported balance
After 2025-06-06 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2025-06-06 · Sale · Disposed 38,807 · Balance 192,212 F1: These 4,693 shares were sold through fifty trades at prices ranging from $3.95 to $3.99 per share. The average of all trades was $3.96 per share as shown. F2: These 38,807 shares were sold through one hundred forty-seven trades at prices ranging from $3.75 to $3.92 per share. The average of all trades was $3.80 per share as shown. |
| Common StockSEC Table I · non-derivative | Direct | 192,212 |
Reported balance
Holding disclosure · report date 2025-06-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 192,212 |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2026-02-23 | Direct | 0 |
Reported balance
After 2025-06-05 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2025-06-05 · Exercise / conversion · Disposed 4,693 · Balance 0 F3: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2026-02-23 | Direct | 0 |
Reported balance
After 2025-06-06 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2025-06-06 · Exercise / conversion · Disposed 38,807 · Balance 0 F3: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2027-02-21 | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2025-06-05 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 50,000 F3: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2028-05-23 | Direct | 80,000 |
Reported balance
Holding disclosure · report date 2025-06-05 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 80,000 F3: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.51 · Expires 2029-05-22 | Direct | 16,500 |
Reported balance
Holding disclosure · report date 2025-06-05 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 16,500 F3: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.45 · Expires 2027-06-18 | Direct | 90,000 |
Reported balance
Holding disclosure · report date 2025-06-05 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 90,000 F3: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $4.17 · Expires 2028-12-28 | Direct | 90,000 |
Reported balance
Holding disclosure · report date 2025-06-05 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 90,000 F3: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.17 · Expires 2029-12-20 | Direct | 72,000 |
Reported balance
Holding disclosure · report date 2025-06-05 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 72,000 F3: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.61 · Expires 2030-12-27 | Direct | 12,600 |
Reported balance
Holding disclosure · report date 2025-06-05 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 12,600 F3: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $2.44 · Expires 2031-12-31 | Direct | 22,500 |
Reported balance
Holding disclosure · report date 2025-06-05 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 22,500 F3: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
Filing footnotes · ownership attribution and instrument terms
F1: These 4,693 shares were sold through fifty trades at prices ranging from $3.95 to $3.99 per share. The average of all trades was $3.96 per share as shown.
F2: These 38,807 shares were sold through one hundred forty-seven trades at prices ranging from $3.75 to $3.92 per share. The average of all trades was $3.80 per share as shown.
F3: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2018 Filed May 24, 2018 22:34 UTC | SOLESENCE, INC. NANX · Entity 7041 | GrantCommon Stock (right to purchase) · Derivative | 80,000 | $0.82 Strike: $0.82 | $65,600.00 |
DisclosureSEC source: 0001209191-18-033144 · doc4.xml · derivative · entry 7 Cureton Kevin · CIK 0001563513 · VP Sales & Mktg & Bus Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2028-05-23 F1 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. Read SEC document |
| May 23, 2018 Filed May 29, 2018 15:01 UTC Amendment | SOLESENCE, INC. NANX · Entity 7041 | GrantCommon Stock (right to purchase) · Derivative | 80,000 | $0.82 Strike: $0.82 | $65,600.00 |
DisclosureSEC source: 0001209191-18-033695 · doc4a.xml · derivative · entry 7 Cureton Kevin · CIK 0001563513 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2028-05-23 F1 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 21:25 UTC | SOLESENCE, INC. NANX · Entity 7041 | GrantCommon Stock (right to buy) · Derivative | 50,000 | $0.68 Strike: $0.68 | $34,000.00 |
DisclosureSEC source: 0001209191-17-013248 · doc4.xml · derivative · entry 6 Cureton Kevin · CIK 0001563513 · VP Sales & Mktg & Bus Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-02-21 F1 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.